Guillain-Barré Syndrome Following the Administration of Adenovirus Vector-Based COVID-19 Vaccine
Related Experiment Video
Updated: Jul 18, 2025
Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
Mardy L Lee1, Juan Miguel P Bautista1
1Neurology, Quirino Memorial Medical Center, Quezon City, PHL.
Insights
A case study details Guillain-Barré syndrome (GBS) following adenovirus vector-based COVID-19 vaccination. Further research is needed to confirm the link between this vaccine type and GBS adverse events.
Area of Science:
- Neurology
- Immunology
- Vaccinology
Background:
- The global rollout of coronavirus disease 2019 (COVID-19) vaccines aims to reduce disease impact.
- Monitoring vaccine side effects is crucial for assessing safety and efficacy.
- Guillain-Barré syndrome (GBS) has been reported post-COVID-19 vaccination, particularly with adenovirus vector-based vaccines.
Observation:
- This report presents a case of GBS in a patient following adenovirus vector-based COVID-19 vaccination.
- The patient experienced diarrhea and fever one day post-vaccination.
- Seven days later, the patient developed bilateral symmetrical weakness and absent deep tendon reflexes.
Findings:
- The observed symptoms are consistent with Guillain-Barré syndrome.
- While a temporal association exists, direct causality between the COVID-19 vaccine and GBS is not definitively established in this case.
- Further investigation is required to confirm any potential link.
Implications:
- Continuous assessment of vaccine benefits and risks is essential for pandemic management.
- Robust post-vaccination surveillance and national reporting systems are vital for identifying potential adverse event links.
- Prospective studies and clinical trials are necessary to thoroughly investigate the association between adenovirus vector-based COVID-19 vaccines and GBS.
Abstract:
As countries worldwide deployed their respective coronavirus disease 2019 (COVID-19) vaccination programs to mitigate the risk of COVID-19 to their citizens, several side effects and complications from the use of the various types of COVID-19 vaccines were documented and are continued to be monitored to further study the safety and efficacy of these vaccines. One such complication, the Guillain-Barré syndrome (GBS), was reported in some individuals who received a COVID-19 adenovirus vector-based vaccine. In this particular report, we describe one such case. The patient had diarrhea and fever one day after vaccination, which was a triggering event. Seven days post vaccination, the patient had bilateral symmetrical weakness with absent deep tendon reflexes. However, causality between the vaccine administered and the suspected adverse reaction cannot be readily assumed. The benefits and risk profiles of each available vaccine should be assessed continuously for it to be improved and truly useful in this pandemic. Thorough post-vaccination surveillance, along with national reporting mechanisms are needed to help establish and confirm possible links between GBS and adenovirus vector-based COVID-19 vaccines. This link needs to be probed further in prospective studies and clinical trials.
